We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.40 | 7.27% | 5.90 | 64,061,375 | 16:35:10 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 5.70 | 6.00 | 7.26 | 5.10 | 5.90 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | -2.92M | -0.0070 | -8.14 | 22.9M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:10 | O | 250,000 | 6.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 28/1/2025 | 14:28 | ALNC |  IN BRIEF: ImmuPharma notes share price surge after novel findings |
| 28/1/2025 | 12:57 | UK RNS | Immupharma PLC Response to Share Price Movement |
| 09/1/2025 | 11:21 | ALNC | IN BRIEF: ImmuPharma shares climb on breakthrough autoimmune findings |
| 09/1/2025 | 07:00 | UK RNS | Immupharma PLC Breakthrough Findings into Autoimmune Diseases |
| 08/1/2025 | 07:00 | UK RNS | Immupharma PLC IMM at JP MORGAN CONFERENCE & BIOTECH SHOWCASE |
| 23/12/2024 | 07:00 | UK RNS | Immupharma PLC Change of Auditor |
| 10/12/2024 | 14:36 | UK RNS | Immupharma PLC Holding(s) in Company |
| 04/12/2024 | 07:00 | UK RNS | Immupharma PLC Appointment of Company Secretary |
| 09/9/2024 | 15:46 | ALNC | ImmuPharma narrows losses in first half as expenses fall |
| 09/9/2024 | 11:45 | ALNC | ImmuPharma obtains second warrant extension with Incanthera |
Immupharma (IMM) Share Charts1 Year Immupharma Chart |
|
1 Month Immupharma Chart |
Intraday Immupharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 28/1/2025 | 18:49 | IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES | 39,137 |
| 10/1/2025 | 15:00 | IMM - 16p minimum, due soon | 13 |
| 10/1/2025 | 12:45 | (IMM) ImmuPharma PLC boss excited by “blockbuster potential” of Lupuzor | 82 |
| 10/10/2022 | 12:36 | Immupharma | - |
| 27/7/2022 | 13:08 | IMMUPHARMA - Let's Talk about the Negatives | 389 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-01-28 17:30:41 | 5.78 | 415 | 23.99 | O |
| 2025-01-28 17:28:47 | 6.20 | 129 | 8.00 | O |
| 2025-01-28 17:28:42 | 6.20 | 674 | 41.79 | O |
| 2025-01-28 17:28:17 | 6.25 | 250,000 | 15,625.00 | O |
| 2025-01-28 17:27:45 | 5.85 | 130,000 | 7,605.00 | O |
| Top Posts |
|---|
Posted at 28/1/2025 08:20 by Immupharma Daily Update Immupharma Plc is listed in the Finance Services sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 5.50p.Immupharma currently has 416,440,000 shares in issue. The market capitalisation of Immupharma is £23,737,080. Immupharma has a price to earnings ratio (PE ratio) of -8.14. This morning IMM shares opened at 5.90p |
Posted at 28/1/2025 12:59 by sphere25 Told ya....CIRCUS.And now they have had to try to clarify things here following that podcast: ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, notes the recent movements in its share price. As announced on 9 January 2025, the Company has made innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. This new discovery, conducted by the Company's R&D subsidiary ImmuPharma Biotech, has yielded data that provides novel insights into autoimmune disease mechanisms. Through this research, the Company is making a significant step towards personalised medicine in SLE and other autoimmune diseases. (Link: The ImmuPharma team also attended the JP Morgan and Biotech Showcase healthcare conferences earlier this month. Attending both meetings gave the ImmuPharma team the opportunity to continue positive discussions with a number of global BioPharma companies, that have already expressed an interest in P140 and its unique approach to treating autoimmune diseases. ImmuPharma is not aware of any further material commercial or operational reason for the significant share price movements, however, the Company will continue to update the market on developments, both commercially and scientifically, when appropriate, over the next period. So they have clarified what they can, except they haven't clarified alot. Wish I knew if they had the NEXT BIG THING that they say noone else has |
Posted at 17/1/2025 08:42 by wigwammer Well the shares are still 100%+ above the undisturbed price, nob, so a little premature to say that. But I'm sure your spite is impatient. One would think with MIN and DEMG leaving the market you might be better reflecting on self, than reflecting on IMM. Atb |
Posted at 13/1/2025 11:05 by putinaire IMM @IMMinentBoom |
Posted at 10/1/2025 18:24 by putinaire It was an impressive end to week. To close above the bar when most would have been offloading little stock movers including this one, (into wknd) was impressiveSupported by maker or a mix. Seems to be news in the price since the last rns. But cant be a related update at this stage so not sure what Great week next week. The hard share price work done |
Posted at 10/1/2025 10:43 by putinaire Putinaire - 09 Jan 2025 - 13:28:27 - 38794 of 38908 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMMGot a feeling, this is not the biggest day at all you know ........ Not saying it's today. Dunno. But yesterday was not the big move at all |
Posted at 09/1/2025 11:32 by zen12 Misleading is the share price rise here, it's not 98% cos yesterday buy price was 1.35 ish, so more 75% so far |
Posted at 09/1/2025 09:29 by wigwammer "But Nobby may well be right." The market cap is £8m, and if nobs consensual view is right you might lose some money, tomboy. But the key thing to consider from this valuation is - what happens to the share price if he is wrong... ATB |
Posted at 09/1/2025 09:21 by tomboyb I was just going to ask your opinion Nobby -IMM have data correlating to auto-immune mechanisms. And will be increasing a number of patents for P140. I presume this is specific to P140 not generic (although it sounds it) - No release of data due to patent pending? - |
Posted at 04/8/2022 07:42 by mudbath Thanks for providing some balance, supernumerary and 1bond.So much more edifying than the trite "big plunge coming tomorrow morning" and "Tim is a disgrace!" contributions. The IMM share price might indeed weaken further . In this event, I would hope to benefit from taking a decent position. |
Posted at 12/5/2022 20:46 by mudbath The IMM share price moves as if on a snakes and ladders board where the trades(or dice)that should determine its ascent or descent apparently having no influence.Nevertheless, it is a great stock from which to extract a daily margin, as the MMs seem happy to part with the shares in the morning at 5.75p only to seek their return at 6p or above, after lunch. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
